Fiorinda Muhaj, MD

Peer-Reviewed Articles

1. Likki S, Stender C, Ivan D, Muhaj F. Progressive Immunotherapy-Related Mucocutaneous Eruption with Severe Rebound to Extensive Epidermal Necrolysis Upon Immunosuppression Tapering. JEADV Clin Pract. e-Pub 2026.
2. Sina N, Muhaj F, Lenskaya V, Ivan D, Prieto VG, Curry JL. Bispecific Dual-Immune Checkpoint Inhibitor-Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients. Am J Dermatopathol 53(5):422-426, 2026. e-Pub 2026. PMID: 41548937.
3. He LJ, Hegazy S, Aung PP, Muhaj F, Nagarajan P, Choksi A, Ciurea AM. Dermatologic toxicities associated with novel pan-RAS/RAF inhibitors. Am J Dermatopathology. Am J Dermatopathology, 2026. e-Pub 2026. PMID: 41548937.
4. Hornick NI, Billo A, Fey RM, Hawkins RM, Muhaj FF, Richards KN, Patel AB, Schenkel JM, Pauken KE, Moran AE. IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planus. bioRxiv. e-Pub 2026. PMID: 42244739.
5. Likki, S, Lee, KP, Muhaj, FF, Wang, W, Lin, P, Cho, WC, Ivan, D, Torres Cabala, CA, Fayad, LE, Curry, JL. Diffuse cutaneous ALK-immunoreactive histiocytosis with MEF2C::FLT3 fusion. JAAD Case Reports 65:233-236, 2025. e-Pub 2025. PMID: 41211348.
6. Alsawas, M, Muhaj, FF, Aung, PP, Nagarajan, P, Cho, WC. Syringocystadenoma Papilliferum-Like Features in Poroma. American Journal of Dermatopathology 46(12):871-874, 2024. e-Pub 2024. PMID: 39422612.
7. Muhaj, FF, Tran, J, Dai, J, Pacha, O, Patel, A. A retrospective case series of eight patients with epidermal growth factor receptor inhibitor–induced cutaneous toxicities managed with dupilumab. JAAD Case Reports 54:17-22, 2024. e-Pub 2024. PMID: 39583056.
8. Kovalenko I, Swamanathan M, Morse D, Ciurea AM, Muhaj F, Torres-Cabala C. Temporal Dynamics and Efficacy of CAR-T Cell Therapy in B-ALL with Extramedullary Cutaneous Involvement: A Case Report and Discussion. Ann Case Report. ACRT Journal, 2023. e-Pub 2023.
9. Kennedy AM, Muhaj FF, Tschen JA, Silapunt S. Linear lichen planus pigmentosus of the face with histological findings of lichen planopilaris - an uncommon variant of lichen planus. Dermatol Online J 27(4), 2021. e-Pub 2021. PMID: 33999582.
10. Ren V, Muhaj F, Haydel D, Chan AJ. Firm, hyperpigmented subcutaneous nodule in the inguinal fold of an infant. Dermatol Online J, 2018. e-Pub 2018. PMID: 30142741.
11. Cho WC, Muhaj F, Gunther JR, Tang G, Torres-Cabala CA. Gains of DUSP22-IRF4: Unusual Non-rearranged DUSP22-IRF4 Chromosomal Alterations in Primary Cutaneous Anaplastic Large Cell Lymphoma. Am J Dermatopathol.
12. Stender C, Likki S, Ivan D, Muhaj F. Immune Checkpoint Inhibitor-Associated Anhidrosis: Case Report and Review of a Rare Cutaneous Toxicity. JAAD Case Rep.
13. Patel AB, Purim O, Wainberg ZA, Rotemberg V, Imanirad I, Dotan E, LeBoeuf N, Khoury J, Zuniga R, Marballi A, Tahover E, Veluvolu A, Bailey S, Greenberg DB, Akhtar A, Pacha O, Muhaj FF, Hecht J, Miller KD, Guggina LM, Wookey V, Miel P, Vankayala H, Ryvo L, Ramachandra S, Benjamin JE, Shelach N, Corn BW, Lacouture ME, Ribas A. A topical BRAF inhibitor for acneiform rash from anti-EGFR therapies. J Clin Oncol.

Review Articles

1. Riew GJ, Canales AL, Aung PP, Shi CR, Muhaj F. Dermatologic Adverse Events Associated with Antibody-Drug Conjugate Loncastuximab: A Retrospective Multicenter Cohort Study. J Am Acad Dermatol 94(6):1855-1857, 2026. e-Pub 2026. PMID: 41730432.
2. Muhaj F, Padmavathi KV, Moody, Brown A, Patel AB. Mucocutaneous adverse events to immune checkpoint inhibitors. Front Allergy, 2023. e-Pub 2023. PMID: 36938327.
3. Muhaj FF, George SJ, Tyring SK. Bacterial antimicrobial resistance and dermatological ramifications. Br J Dermatol 187(1):12-20, 2022. e-Pub 2022. PMID: 35083740.
4. Muhaj FF, George SJ, Nguyen CD, Tyring SK. Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics. J Am Acad Dermatol 86(6):1207-1226, 2022. e-Pub 2022. PMID: 35122895.
5. George S, Muhaj FF, Nguyen CD, Tyring SK. Part I Antimicrobial resistance: Bacterial pathogens of dermatologic significance and implications of rising resistance. J Am Acad Dermatol 86(6):1189-1204, 2022. e-Pub 2022. PMID: 35122894.

Other Articles

1. Hajjar J, Stephen B, Aaroe AE, Aiche MM, Al-Zubidi N, May, Ameri, Brooks KA, Carabenciov ID, Chambers MS, Lateef A, Chaudhry, Connors JM, Davies MA, Debnath KC, Faiz SA, Fuller CD, Goepfert RP, Gombos DS, Gupta S, Hadfield M, Hutcheson KA, Islam S, Jalal A, Jayasekara M, Khalid A, Jazieh, Khine A, Kim P, Lai SY, Lei YL, Li YJ, Markovic SN, McMillan H, Moreno AC, Muhaj F, Nader M, Otun A, Pacha O, Palaskas NL, Patel AB, Patel N, Zoe, Quandt, Sagiv O, Sharon E, Shatila M, Sheshadri A, SuarezAlmazor ME, Thomas AS, Wang Y, Won A, Zhang HC, Aung, Naing The immune checkpoint inhibitors journey: From early promise to lasting impact. Journal of Immunotherapy and Precision Oncology.
2. Likki, S, Lee, K, Nagarajan, P, Ivan, D, Cho, WC, Muhaj, FF Blue-Gray Papules on the Chest and Face. JEADV Clinical Practice 5(1):326-329, 2026.

Abstracts

1. Riew G, Shi C, Muhaj F. Cutaneous toxicities to antibody-drug conjugate loncastuximab tesirine: A multicenter retrospective analysis. European Academy of Dermatology and Venerology.
2. Lee K, Likki S, Muhaj F, Nagarajan P, Ivan D, Cho WC. Multicentric Endocrine Mucin-Producing Sweat Gland Carcinoma harboring NF2 Mutation. American Society of Dermatopathology.
3. Lee K, Muhaj F, Wang W, Lin P, Fayad LE, Curry JL. ALK-immunoreactive histiocytosis without ALK rearrangement. American Society of Dermatopathology.
4. He JL, Hegazy S, Muhaj F, Aung PP, Nagarajan P, Nelson KC, Torres-Cabala C, Prieto V, Curry JL. Dermatologic Toxicities Associated with Novel PanRAS/RAF Small Molecule Inhibitors. American Society of Dermatopathology.
5. Hegazy S, Curry JL, Muhaj F, Dai J, Tang G, Huen A, Nagarajan P, Aung PP, Prieto VG, Francisco Vega-Vazquez F, Medeiros J, Torres-Cabala CA, Cho WC. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders with IRF4/DUSP22-Associated Chromosomal Alterations, including Rearrangements, Gains, and Deletions: A Clinicopathological, Immunohistochemical, and Molecular Analysis of 22 Patients. Academy of Pathology.

Book Chapters

1. Phillips R, Muhaj F, Pacha O, Richards KN, Patel A. Cutaneous Adverse Effects of Anti-cancer Agents including Immunotherapy. Comprehensive Dermatologic Drug Therapy.

Letters to the Editor

1. Muhaj FF, Tyring SK. Response to Chu et al's "Developing and implementing approaches to limit antimicrobial resistance". J Am Acad Dermatol 88: e51-e52, 2023.